AdipoGen Life Sciences


CHF 95.00
In stock
AG-CR1-3619-M01010 mgCHF 95.00
AG-CR1-3619-M05050 mgCHF 250.00
More Information
Product Details
Synonyms Jardiance; BI-10773; (2S,3R,4R,5S,6R)-2-[4-Chloro-3-[[4-[(3S)-oxolan-3-yl]oxyphenyl]methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol
Product Type Chemical


MW 450.9
CAS 864070-44-0
Purity Chemicals ≥98% (HPLC)
Appearance White solid.
Solubility Soluble in DMSO. Slightly soluble in water or ethanol.
Identity Determined by 1H-NMR.
Smiles OCC1O[C@H](C(O)[C@@H](O)[C@@H]1O)C1=CC(CC2=CC=C(O[C@H]3CCOC3)C=C2)=C(Cl)C=C1
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice Keep cool and dry.
Use/Stability Stable for at least 3 years after receipt when stored at -20°C.
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF
  • Antidiabetic agent.
  • Potent and selective sodium glucose co-transporter 2 (SGLT-2) inhibitor. >300-fold selectivity over SGLT-1, 4, 5 and 6.
  • SGLT-2 is found almost exclusively in the proximal tubules of nephronic components in kidneys. Inhibition of SGLT-2 reduces blood glucose by blocking renal glucose reabsorption and thereby increasing urinary glucose excretion (UGE).
  • Shown to preserves β cell mass and restore glucose homeostasis.
Product References
  1. BI-10773, a sodium-glucose cotransporter 2 inhibitor for the potential oral treatment of type 2 diabetes mellitus: I. Aires & J. Calado; Curr. Opin. Investig. Drugs 11, 1182 (2010)
  2. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors: R. Grempler, et al.; Diabetes Obes. Metab. 14, 83 (2012)
  3. Long-term treatment with empagliflozin, a novel, potent and selective SGLT-2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats: L. Thomas, et al.; Diabetes Obes. Metab. 14, 94 (2012)
  4. Empagliflozin (BI 10773), a potent and selective SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. L. Seman, et al.; Clin. Pharmacol. Drug Dev. 2, 152 (2013)
  5. The SGLT2 Inhibitor Empagliflozin for the Treatment of Type 2 Diabetes Mellitus: a Bench to Bedside Review: J.B. McGill; Diabetes Ther. 5, 43 (2014) (Review)
  6. Empagliflozin, a sodium glucose co-transporter 2 inhibitor, in the treatment of type 1 diabetes: E.M. Lamos, et al.; Expert Opin. Investig. Drugs 23, 875 (2014) (Review)
  7. The sodium glucose cotransporter type 2 inhibitor empagliflozin preserves β-cell mass and restores glucose homeostasis in the male zucker diabetic fatty rat: H.H. Hansen, et al.; J. Pharmacol. Exp. Ther. 350, 657 (2014)
  8. Empagliflozin improves insulin sensitivity of the hypothalamus in humans with prediabetes: A randomized, double-blind, placebo-controlled, phase 2 trial: S. Kullmann, et al.; Diabetes Care (Epub ahead of print) (2021)
  9. Gliflozins Have an Anti-Inflammatory Effect on Renal Proximal Tubular Epithelial Cells in a Diabetic and Inflammatory Microenvironment In Vitro: B. Koch, et al.; Int. J. Mol. Sci. 24, 1811 (2023)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.